Medical Research Finder

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) & Drugs/Treatments

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Clinical Outcomes in NAFLD Trials

The primary clinical outcomes observed in trials for Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) include:

Hepatic fat content

Improvement in hepatic histology (such as in Non-Alcoholic Steatohepatitis (NASH) or fibrosis)

Adverse events (safety)

Goals and Strategies in NAFLD Treatment

The ultimate goal in treating NAFLD is to prevent mortality and progression to [cirrhosis](brain://v0wDqmafJUS7SD4b7yLCYA/LiverFibrosisCirrhosi…

References (Sources)

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
Che et al. 2022f Front Endocrinol (Lausanne) 13:1002916
Review
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges
Alkhouri 2020
Non-alcoholic fatty liver disease: the diagnosis and management
Abd El-Kader & El-Den Ashmawy 2015 World J Hepatol 7: 846-58
Review
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Cherubini et al. 2021 Expert Opinion on Therapeutic Targets 25(12): 1033-1043
Review
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease
Koopman et al. 2019 Aliment Pharmacol Ther. 50(6): 628-639
Review
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani et al. 2018 Hepatology 67: 328-357
Review
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh et al. 2017a World J Gastroenterol. 23(36): 6549-6570

AI Chat

5/29/2026

Chat with our artificial intelligence: